🔎 Trials Near Me

Hjem › Akut bifænotypisk leukæmi › Massachusetts

Akut bifænotypisk leukæmi kliniske forsøg i Massachusetts

5 studier for Akut bifænotypisk leukæmi søger deltagere på steder i Massachusetts.

Byer i Massachusetts

Officiel studietekst (engelsk)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Dana-Farber Cancer Institute, Boston
  • UMass Memorial Medical Center - University Campus, Worcester
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
  • Baystate Medical Center, Springfield
  • og 1 flere
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241

Venetoclax Basket Trial for High Risk Hematologic Malignancies

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 1 til 40 · Alle køn · Opdateret 12. mar. 2026 · NCT05292664

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.